Am. J. Respir. Crit. Care Med., Volume 161, Number 2, February 2000, 406-413

Long-term Follow-up of Pulmonary Function in Patients with Nasal Polyposis

CATHERINE LAMBLIN, ANNE BRICHET, THIERRY PEREZ, JEAN DARRAS, ANDRÉ BERNARD TONNEL, and BENOÎT WALLAERT

Clinique des Maladies Respiratoires, Hôpital A. Calmette, CHRU, Lille, France; and Service d'Oto-Rhino-Laryngologie, Hôpital Claude Huriez, CHRU, Lille, France

The outcome of asthma and/or nonspecific bronchial hyperresponsiveness (BHR) associated with nasal polyposis (NP) is uncertain. Over a 4-yr period, we investigated the long-term changes of pulmonary function and BHR in 46 patients with NP. Each subject was assessed for nasal symptoms and tested for allergy skin prick tests, serum total IgE, spirometry, and carbachol challenge at baseline before initiating any treatment (T0). Nasal symptoms evaluation, spirometric measurements, and carbachol challenge were repeated at T1 and at T2 (respectively, 12.7 ± 0.9 and 47.9 ± 2.2 mo after T0). In addition, bronchodilator response was measured at T2. At T0, 25 patients exhibited BHR and 16 of 25 were asthmatic. All patients were treated first with topical steroids for 6 wk (beclomethasone 600 µg/d). Eighteen patients were successfully treated with topical steroids (topical steroids responders). Intranasal ethmoidectomy was performed in 28 patients who did not improve with topical steroids alone (topical steroids nonresponders). Nasal score improved at T1 and remained improved at T2 as compared with T0 in both groups (p < 0.005). Topical steroids nonresponders demonstrated a significant decrease of FEV₁, FEV₁/FVC ratio, and FEF_25-75 at T1 (p < 0.05) and at T2 (p < 0.0005), whereas no significant change was observed in FEV₁ and FEV₁/FVC ratio in responders. FEV₁ (%) between T2 and T0 was not related to the presence of asthma, BHR, or atopy. Bronchodilator response at T2 was similar in the two groups. BHR did not significantly change over the 4-yr follow-up period in the two groups. No change in pulmonary symptoms and/or asthma severity occurred. Our results show that nonreversible airflow obstruction appears over a 4-yr follow-up period in topical steroids nonresponders patients with NP requiring nasal surgery. The long-term contribution of these changes to the development of respiratory symptoms in patients with NP remains to be documented. Lamblin C, Brichet A, Perez T, Darras J, Tonnel AB, Wallaert B. Long-term follow-up of pulmonary function in patients with nasal polyposis.

This article has been cited by other articles:

				S. Ragab, G. K. Scadding, V. J. Lund, and H. Saleh Treatment of chronic rhinosinusitis and its effects on asthma Eur. Respir. J., July 1, 2006; 28(1): 68 - 74. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580. [Full Text] [PDF]

				C. LAMBLIN, F. BOLARD, P. GOSSET, A. TSICOPOULOS, T. PEREZ, J. DARRAS, A. JANIN, A. B. TONNEL, Q. HAMID, and B. WALLAERT Bronchial Interleukin-5 and Eotaxin Expression in Nasal Polyposis . Relationship with (A)symptomatic Bronchial Hyperresponsiveness Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1226 - 1232. [Abstract] [Full Text]